Results are preliminary and unaudited. This document contains "forward-looking statements"—that is, statements related to future, not past, events or performance. These forward-looking statements include information related to future events and results, as well as our future financial condition and performance, and are subject to inherent risks, uncertainties, and assumptions. Future events and results could differ materially from those expressed in or indicated by these statements due to a variety of factors, including the factors set forth herein. See "GE’s Risk Factors" for a discussion of these and other factors.

GE’s Risk Factors include, among others, the following:

1. General economic and financial conditions.
2. Changes in capital markets and interest rates.
3. Changes in laws and regulations, including taxation and trade policies.
5. Capital expenditures and capital needs.
6. Product development and commercialization risks.
7. Globalization and management of international operations.
8. Operational risks.
9. Litigation and regulatory proceedings.

Investor alerts: GE uses e-mail as an informal way to disseminate important information to investors, including GE’s financial results, investor presentations, and other information. You can sign up to receive these alerts in the "Investor Alerts" section of the investor relations section of our website at www.ge.com.

In this document, "GE" refers to the Industrial businesses of the Company including GECS on an equity basis. "GE (ex. GECS)" and/or "Industrial" refer to GE’s Industrial businesses.

Leadership technologies, global footprint, diverse portfolio.
Global reach

**Americas**
- Revenue ~$8.3B
- Employees ~23,000

**Europe, Middle East & Africa**
- Revenue ~$4.7B
- Employees ~15,000

**Asia**
- Revenue ~$3.0B
- Employees ~10,000

**Developed Markets**
- Moderate growth in traditional equipment markets
- High growth adjacent markets
- Strong services and solutions

**Developing Markets**
- Double-digit growth
- Healthcare build-out
- “In-country, for-country” footprint

---

Growing GE Healthcare revenues

($ in billions)

- **1998**
  - Life Science
  - Mdx
  - Serv & HCIT
  - Emer. Equip
  - Dev. Equip
  - Total: $4.6

- **2009**
  - Life Science
  - Mdx
  - Serv & HCIT
  - Emer. Equip
  - Dev. Equip
  - Total: $16.0

- **2010**
  - Life Science
  - Mdx
  - Serv & HCIT
  - Emer. Equip
  - Dev. Equip
  - Total: $24.6

**Growth drivers**
- Steady growth driven by life sciences and precision diagnostics: ~10%
- Consistent service growth driven by installed base, solutions and IT: ~35%
- Booming emerging markets: ~15%
- Modest growth driven by recovery in developed markets: ~30%

---

CAGR: 12%
Elevating the business performance

✓ Operational excellence: driving cash, cost and regulatory compliance
✓ More and better New Product Introductions
✓ Big investments in global footprint
✓ Changing our culture with healthy imagination

Operational excellence

<table>
<thead>
<tr>
<th>CM rate</th>
<th>Base Cost</th>
<th>CFOA</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>48%</td>
<td>$5.7B</td>
<td>$2.5B</td>
<td></td>
</tr>
<tr>
<td>48%</td>
<td>$5.3B</td>
<td>$3.5B</td>
<td>Intensified focus on working capital</td>
</tr>
</tbody>
</table>

- Restructured ~7% of workforce ... ~$400MM annual savings
- Eliminated ~100 rooftops ... ~12% reduction
- Indirect cost actions... ~$420MM '09 savings
- ~4% deflation ... ~$150MM benefit in 2009

Stronger focus on margins and cash
Healthcare growth through NPI

R&D Spend

- $1.0B in 2008
- ~$1.1B+ in 2010

Global NPIs
- 50 in 2008
- ~100 in 2010

~10,000+ GE & GEHC researchers, scientists and engineers

Brivo™ MR
- Shanghai, China
- Munich, Germany
- Bangalore, India
- Niskayuna, NY

~$1.1B+
- Wide-bore MR
- ~$1.5
- Other products

Strongest portfolio in years...more coming

Globalization through localization

China + India

- $1.0 in 2008
- ~$1.5 in 2010

Growth drivers

- Reorganized business ... local leaders reporting to CEO
- Building out commercial reach ... adding ~1000+ resources
- Building local supply chain capability...10 factories
- Launching new, unique products for local market

Products developed

- Brivo™ CT
- Brivo™ MR
- MAC® 400
- MAC® 800
- Lullaby™ Warmer

Booming healthcare markets
Changing the culture: **healthymagination**

Reducing cost, touching more people, and delivering better quality

- **Cost savings**
  - Greater efficiency
  - Therapy decision-support
  - Managing chronic diseases
  - 15% ↓

- **Access improvement**
  - Screening for life-threatening conditions
  - Technology to extend reach (remote access and portability)
  - 15% ↑

- **Quality improvement**
  - Reducing medical errors
  - Improving diagnostic precision
  - Remote medicine/monitoring
  - 15% ↑

Products with clinical & economic value propositions
New products for underserved markets
Strong demand for healthcare IT and solutions

GE knows how to win in this environment

---

Healthcare quarterly order V%

- **HCS equipment**: recovery in developed markets, developing markets up double-digit
- **HCS service**: growth continues at 3-5%, ramping solutions business
- **Life Sciences**: backlog up 40% ... bioprocess rebound
- **HCIT**: orders up 7% ... "meaningful use" and stimulus

Stronger markets, better products, improved cost position
Looking ahead ... healthcare trends

**Reality**

- Demand drivers remain strong despite economic pressure
- Biology + Life Sciences transforming diagnosis and therapy
- Payors & providers want clinical quality + efficiency
- Care moving outside of hospitals to save cost

**GEHC Opportunities**

- Chronic disease and aging of society
- Emerging market build-out
- Newly-insured in the USA
- Pipeline of precision molecular diagnostics in development for neurology, cardiology and oncology applications
- Life sciences portfolio enabling monoclonal antibody and cell therapies
- IT solutions to provide clinical decision support & productivity
- Performance Solutions business to help healthcare organizations boost quality + efficiency
- GEHC developing mobile, easy-to-use, affordable products
- Remote monitoring technologies to support home health and assisted living

Healthcare trends create opportunities

**Demographic challenges**

- Projected chronic disease deaths worldwide 2005-2015*
- Heart disease + stroke leading cause of death
- World Population: aged 60+ in billions 1950-2050**

**China and India build-out**

- China: $123B HC reform
  - Expanding public health
  - Increased rural insurance
  - Relatively open and accessible market
  - Attractive market for Life Sciences

- India: rising consumer, government spend
  - 16% of world pop, 20% of world disease
  - Government health & personal spend growing (7% to 9% in 5 years)

**US Healthcare reform**

- 32MM newly insured
- Worst case is neutral impact ... tax offset by volume
- †Demand for cost-reducing technologies & solutions
- Healthcare IT stimulus
- Massachusetts experience: increased volumes and capacity constraints
Driving innovative diagnosis & therapy

Precision molecular diagnostics enable new & more targeted treatments

- Clinical and economic needs
- Fluciclatide (proposed indication: neurology, cardiology, oncology)
- Focus on neurology, cardiology, oncology
- GEHC precision diagnostics
- Products and indications are not approved by the US Food & Drug Administration
- Better diagnostics help determine right treatments, which reduce side-effects and improve cost + safety
- GE wins as market matures
- GE manufacturing for researchers today
- Cell therapy: Blockbuster potential
- Cell therapy: Blockbuster potential
- Technology + advisory capability driving system-wide optimization
- Advisory/Change mgt + Process Technology
- OR scheduling optimization
- Lean Six Sigma Change Acceleration
- Qualibria™: enabling best-practice, higher quality care resulting in lower costs
- $123 billion spent on patients could have been reduced by $40 billion using Intermountain Healthcare’s standards**
- GE Unique Position
- Enabling customers to:
  - Reduce clinical variability
  - Change management, pathway design, analytics, quality improvement systems... leverage Qualibria™
  - Liberate hidden capacity & reduce waste & error
  - Advisory/Change mgt + Process Technology
  - Optimize Healthcare systems Cost & clinical best practices across care continuum

**GEHC precision diagnostics
- Focus on neurology, cardiology, oncology
- Fluciclatide (amyloid plaque in the brain)
- DaTSCAN™ (Parkinson’s, dementia with Lewy bodies)*
- AdreView™ (proposed indication: heart failure)*
- Fluciclatide (proposed indication: angiogenesis)*
- Collaboration with Eli Lilly in molecular pathology for cancer

GEHC techs enabling new monoclonal antibody & cell-based therapies

- Monoclonal antibody (MAb) growth
- BioPharma Sales (SBI)**
- MAb sales — CAGR ’02-’10E ~11%
- Cell therapy: Blockbuster potential
- Cell Manufacturing opportunity (SBI)**
- MAb sales

Qualibria™: driving better clinical outcomes

- Traditional EMR
  - Automation & documentation of clinical activities
- Qualibria™
  - Real time clinical decision support within workflow

**Company and investor analyst reports

***Data from Intermountain Healthcare, 2006
Care moving out of hospitals to save costs

**Mobile/Affordable**
Easy to Use for non-MDs

- **Extremity MR**
  - Optima™ MR 380s
  - 90% lighter and 55% smaller
  - 60% lower total cost of ownership

- **Handheld Ultrasound**
  - Vscan™
  - Immediate, non-invasive info.
  - during physical exam

- **Portable ECG**
  - MAC® 400
  - Light weight, one-touch,
  - requires minimal training

- **Portable Ultrasound**
  - Venue™ 60
  - Easy to use for immediate decisions

**Remote Monitoring**

- **Home Monitoring**
  - QuietCare®
  - Enable care in lower cost settings such as
  - home or assisted living

- **Intel Home Health Partnership**
  - Partnering with Intel for suite of Home Health®
  - solutions

---

**Summary**

**Consistent financial performance**

- **Healthcare**
  - Looking better
  - +3-5% Revenue
  - +5-10% Profits

**Stronger business model**

- Better products at every price point
- Big emerging markets
- Broader IT & services portfolio for customers
- Leader in advanced diagnostics
- Building out Life Sciences, HCIT & Home Health adjacencies
- Better margins & cash performance

**Improved outlook & performance**

**GE leads: cost + quality + access**